Roche Pharmaceutical Development and Sales Overview

Gazyva (obinutuzumab, RG7159) Immunology development program Indication Phase/study Systemic lupus erythematosus (SLE) Phase III ALLEGORY # of patients N=200 ☐ ■ ARM A: Gazyva 1000mg IV on Day 1 and Weeks 2, 24 and 26. ARM B: Placebo IV Design Primary endpoint Status CT Identifier In collaboration with Biogen IV=Intravenous Percentage of participants who achieve Systemic Lupus Erythematosus Responder Index (SRI) at week 52 ■ FPI Q4 2021 NCT04963296 92 44 Roche Immunology

View entire presentation